Monica Sigovan1, Salim Si-Mohamed2,3, Pierre-Yves Courand4, Brahim Harbaoui2,4, Marc Sapoval4, Sébastien Bros3, Philippe C Douek2,3, Pierre Lantelme2,4, Loic Boussel2,5. 1. Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Bâtiment Blaise Pascal (502, 4ème étage), 7 avenue Jean Capelle, 69621, Villeurbanne Cedex, France. monica.sigovan1@gmail.com. 2. Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, CREATIS UMR 5220, U1206, Bâtiment Blaise Pascal (502, 4ème étage), 7 avenue Jean Capelle, 69621, Villeurbanne Cedex, France. 3. Hospices Civils de Lyon, Department of Radiology, Hopital Cardiologique Louis Pradel, Bron, France. 4. Hospices Civils de Lyon, Department of Cardiology, Hopital de la Croix Rousse, Lyon, France. 5. Hospices Civils de Lyon, Department of Radiology, Hopital de la Croix Rousse, Lyon, France.
Abstract
OBJECTIVES: Endovascular renal denervation (RDN) using catheter-based radiofrequency (RF) ablation has emerged as a potential treatment option for drug-resistant hypertension. Its efficacy is currently under debate. We aimed to evaluate the capability of contrast-enhanced magnetic resonance imaging (MRI) to assess the effects of RDN on the renal arterial wall in patients presenting with drug-resistant hypertension. METHODS: Patients were included prospectively following institutional review board approval and written informed consent. Renal arteries were imaged using a two-dimensional T1-weighted TSE sequence pre- and post-administration of a gadolinium-based contrast agent, before (D0), 2 days (D2) and 6 months (M6) after RDN. Mean enhancement of the wall (mENH) and mean wall thickness (mWT) were compared across time using an ANOVA with repeated measures and post-hoc paired t-test. RESULTS: Follow-up was completed for 23 patients (median age, 57 years; 16 men). The mENH at D2 (96.3 ± 36.0 %) was significantly higher than at D0 (61.1 ± 26.3%, p < 0.001) and M6 (66.1±22.7%, p < 0.001). Similarly, mWT was significantly higher at D2 (3.1 ± 0.4 m) than at D0 (2.7 ± 0.4mm, p < 0.001) and M6 (2.9 ± 0. 5 mm, p = 0.002). CONCLUSIONS: MRI demonstrated abnormalities of the arterial wall 2 days after RDN that had resolved at 6 months. KEY POINTS: • Contrast-enhanced MRI provides anatomic evidence of renal artery RF ablation • Temperature increase related to RF ablation induces transient arterial wall inflammation • Morphological effects observed 2 days post RF ablation are not visible after 6 months.
OBJECTIVES:Endovascular renal denervation (RDN) using catheter-based radiofrequency (RF) ablation has emerged as a potential treatment option for drug-resistant hypertension. Its efficacy is currently under debate. We aimed to evaluate the capability of contrast-enhanced magnetic resonance imaging (MRI) to assess the effects of RDN on the renal arterial wall in patients presenting with drug-resistant hypertension. METHODS:Patients were included prospectively following institutional review board approval and written informed consent. Renal arteries were imaged using a two-dimensional T1-weighted TSE sequence pre- and post-administration of a gadolinium-based contrast agent, before (D0), 2 days (D2) and 6 months (M6) after RDN. Mean enhancement of the wall (mENH) and mean wall thickness (mWT) were compared across time using an ANOVA with repeated measures and post-hoc paired t-test. RESULTS: Follow-up was completed for 23 patients (median age, 57 years; 16 men). The mENH at D2 (96.3 ± 36.0 %) was significantly higher than at D0 (61.1 ± 26.3%, p < 0.001) and M6 (66.1±22.7%, p < 0.001). Similarly, mWT was significantly higher at D2 (3.1 ± 0.4 m) than at D0 (2.7 ± 0.4mm, p < 0.001) and M6 (2.9 ± 0. 5 mm, p = 0.002). CONCLUSIONS: MRI demonstrated abnormalities of the arterial wall 2 days after RDN that had resolved at 6 months. KEY POINTS: • Contrast-enhanced MRI provides anatomic evidence of renal artery RF ablation • Temperature increase related to RF ablation induces transient arterial wall inflammation • Morphological effects observed 2 days post RF ablation are not visible after 6 months.
Authors: Mi Hye Yu; Jae Young Lee; Su Ryoung Jun; Kyung Won Kim; Se Hyung Kim; Joon Koo Han; Byung Ihn Choi Journal: Radiology Date: 2015-07-14 Impact factor: 11.105
Authors: Benjamin Kaltenbach; Dani Id; Jennifer C Franke; Horst Sievert; Marcus Hennersdorf; Jens Maier; Stefan C Bertog Journal: J Am Coll Cardiol Date: 2012-11-07 Impact factor: 24.094
Authors: Dana C Peters; John V Wylie; Thomas H Hauser; Kraig V Kissinger; René M Botnar; Vidal Essebag; Mark E Josephson; Warren J Manning Journal: Radiology Date: 2007-06 Impact factor: 11.105
Authors: Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler Journal: Lancet Date: 2009-03-28 Impact factor: 79.321